A Phase 3 Study of VX-445 Combination Therapy in Cystic Fibrosis (CF) Subjects Heterozygous for F508del and a Gating or Residual Function Mutation (F/G and F/RF Genotypes)
Clinical trial NCT04058353 · COMPLETED
Trial details
- NCT number
- NCT04058353
- Sponsor
- Vertex Pharmaceuticals Incorporated
- Status
- COMPLETED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2019-08-28
- Primary completion
- 2020-06-12
- Enrollment
- 271
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.